Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma

详细信息    查看全文

• 作者：Balaji Venugopal (1)
  Jawaher Ansari (1)
  Michael Aitchison (1) (2)
  Lye Mun Tho (1) (2)
  Roderick Campbell (3)
  Rob J Jones (1) (2)
  
• 关键词：Temsirolimus ; Chromophobe renal cell carcinoma ; Renal cell cancer
• 刊名：BMC Urology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：191KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. / CA Cancer J Clin 2011,61(2):69鈥?0. CrossRef
  2. Gore ME, Larkin JMG: Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. / Br J Cancer 2011,104(3):399鈥?06. CrossRef
  3. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ: The Heidelberg classification of renal cell tumours. / J Pathol 1997,183(2):131鈥?33. CrossRef
  4. Tickoo SK, Amin MB, Zarbo RJ: Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. / Am J Surg Pathol 1998,22(4):419鈥?24. CrossRef
  5. Patard J-J, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. / J Clin Oncol 2005,23(12):2763鈥?771. CrossRef
  6. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. / N Engl J Med 2007,356(22):2271鈥?281. CrossRef
  7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. / N Engl J Med 2007,356(2):115鈥?24. CrossRef
  8. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of Non鈥揷lear-cell histology. / J Clin Oncol 2002,20(9):2376鈥?381. CrossRef
  9. Patel PH, Chadalavada RSV, Chaganti RSK, Motzer RJ: Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma. / Clin Cancer Res 2006,12(24):7215鈥?220. CrossRef
  10. Dutcher J, de Souza P, McDermott D, Figlin R, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G: Effect of temsirolimus versus interferon-伪 on outcome of patients with advanced renal cell carcinoma of different tumor histologies. / Medical Oncology 2009,26(2):202鈥?09. CrossRef
  11. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. / J Clin Oncol 2008,26(1):127鈥?31. CrossRef
  12. Larkin JMG, Fisher RA, Pickering LM, Sohaib SA, Ghosn M, Christmas T, Cordiner RLM, Gore ME: Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. / J Clin Oncol 2011,29(9):e241-e242. CrossRef
  13. Paule B, Brion N: Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. / Anticancer Res 2011,31(1):331鈥?33.
  14. Zardavas D, Meisel A, Samaras P, Knuth A, Renner C, Pestalozzi BC, Stenner-Liewen F: Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. / Case Reports Oncol 2011,4(1):16鈥?8. CrossRef
  15. Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R: Targeting the mTOR pathway in chromophobe kidney cancer. / J Cancer 2012, 3:152鈥?57. CrossRef
  16. Armstrong A: / Phase II Study of Afinitor vs. Sutent in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN). 2012. Current clinical trial. http://clinicaltrials.gov/show/NCT01108445
  17. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/13/26/prepub
  
• 作者单位：Balaji Venugopal (1)
  Jawaher Ansari (1)
  Michael Aitchison (1) (2)
  Lye Mun Tho (1) (2)
  Roderick Campbell (3)
  Rob J Jones (1) (2)
  
  1. Beatson West of Scotland Cancer Centre, 1053, Great Western Road, Glasgow, G12 0YN, UK
  2. Institute of Cancer Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
  3. Monklands Hospital, Monkscourt Avenue, Airdrie, ML6 0JS, UK
  

文摘

Background Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases. The median overall survival of advanced RCC has improved significantly since the advent of tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors. However, high-quality evidence for the use of new generation tyrosine kinase inhibitors in patients with advanced chRCC is lacking. Few published case reports have highlighted the use of temsirolimus in chRCC. Case presentation Here, we report the case of a 36-year-old Caucasian woman with metastatic chRCC with predominantly skeletal metastases who was refractory to sunitinib who demonstrated a durable clinical response to temsirolimus lasting 20 months. We review the available evidence pertaining to the use of new generation molecularly targeted agents, in particular mTOR inhibitors in chRCC and discuss their emerging role in the management of this disease which would aid the oncologists faced with the challenge of treating this rare type of RCC. Conclusion Conducting randomised clinical trials in this rarer sub-group of patients would be challenging and our case report and the evidence reviewed would guide the physicians to make informed decision regarding the management of these patients.